GORE® TAG® Thoracic Branch Endoprosthesis

First-of-its kind FDA approved device designed for simplified, minimally invasive zone 2 TEVAR procedures. Maximize results without the potential risks and complexity of revascularization.

IDE Study outcomes. One year follow-up.

‎

“The GORE^® TAG^® Thoracic Branch Endoprosthesis has the potential to simplify the treatment of Zone 2 LSA revascularization because it is a single device that can be used in a single procedure.”

Michael Dake, M.D.,
Co-national principal investigator
Senior Vice President, University of Arizona Health Services

High patency. Low disabling stroke rate graphic

‎

Michael Dake, M.D.,
Co-national principal investigator
Senior Vice President, University of Arizona Health Services

doctor showing nurse information on tablet

From pre-case planning to device procedural consultation, we are by your side to provide support.

Training needs – Essential technical support with a deep reservoir of product knowledge.
8+ years – Average field representatives’ tenure supporting Gore's aortic devices, building on diverse clinical backgrounds.
Non-commissioned sales force – Our focus is on outcomes.

Contact your Gore Field Sales Associate to learn more.

* For patients treated with TBE compared to those treated TEVAR and surgical LSA revascularization

Squiers JJ, DiMaio JM, Schaffer JM, et al. Surgical debranching versus branched endografting in zone 2 thoracic endovascular aortic repair. Journal of Vascular Surgery 2022;75(6):1829-1836.e3.
GORE^® TAG^® Thoracic Branch Endoprosthesis. [Instructions for Use]. Flagstaff, AZ: W. L. Gore & Associates, Inc. 2022; MD184153. Rev. 1

22796250-EN